This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of intervention
Treatment.
Economic study type
Cost-effectiveness analysis.
Study population
The study population comprised women aged 18 to 39 years with: a cause of infertility potentially solvable by IVF; a maximum of three prior IVF or other assisted reproduction attempts in which oocytes were collected at least once; normal ovulatory cycles; good physical and mental health; and a body weight of 80 to 130% of the ideal body weight.
The exclusion criteria were: infertility caused by endocrine abnormalities such as hyperprolactinaemia, polycistic ovary syndrome, and absence of ovarian function; male infertility; any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound investigation; hypertension; chronic cardiovascular, hepatic, renal, or pulmonary disease; a history of (within 12 months) or current abuse of alcohol or drugs; administration of non-registered investigational drugs within 3 months prior to screening.
Study design
This was an assessor-blind, randomised clinical trial, which was conducted in 18 different IVF centres in Europe. Randomisation was conducted using a list that corresponded to patient boxes in which the medication was kept. The ratio of patients between rFSH and uFSH was 3:2. Double-blinding was not feasible for technical reasons. The patients were followed until the third cycle of IVF was conducted. However, the actual length of and loss to follow-up were not reported.
Analysis of effectiveness
The basis for the analysis of the clinical study was intention to treat. The health outcomes used in the effectiveness study were several measures, which were converted into probability values: hospitalisation due to ovarian hyperstimulation syndrome (OHSS), pregnant-fresh after embryo transfer, pregnant-frozen after thawed transfer, thawed transfer after no pregnancy, embryo transfer after stimulation, and stimulated after no embryo transfer.
The pregnancy rate was the main outcome measure. The study groups were shown to have been comparable at baseline in terms of the demographic and infertility characteristics.
Effectiveness results
The probability values for all cycles were as follows.
The probability of hospitalisation due to OHSS was 0.019 with uFSH, and 0.032 (first and second cycles) and 0.03 (third cycle) with rFSH.
The probability of being pregnant-fresh after embryo transfer was 0.2202 with uFSH and 0.2597 with rFSH.
The probability of being pregnant-frozen after thawed transfer was 0.076 with uFSH and 0.164 with rFSH.
The probability of thawed transfer after no pregnancy was 0.409 with uFSH and 0.527 with rFSH.
The probability of embryo transfer after stimulation 0.831 with uFSH and 0.855 with rFSH.
The probability of stimulation after no embryo transfer was 1 with both uFSH and rFSH.
Clinical conclusions
The effectiveness evidence showed that rFSH was statistically more effective than uFSH in terms of pregnancy rates, but the probability of OHSS was slightly higher with rFSH. The remaining probability values were used as model inputs.
Modelling
A decision tree model was constructed to evaluate the cost-effectiveness of the three alternative treatments for infertile women. The model joined the medical cost and associated outcome per woman undergoing IVF. Following the structure of the tree, women who became pregnant after the first cycle of treatment were considered as a success. Those who did not became pregnant either received a further cycle of IVF treatment or dropped out for non-medical reasons. The process was exhausted when all women had received a maximum of three cycles of treatment. The model was constructed in DATA (version 3.5, TreeAge Software).
Methods used to derive estimates of effectiveness
An expert panel was contacted for data reflecting treatment patterns in the UK and to estimate probability values that were unavailable in the literature. Each member of the panel was sent a questionnaire and their responses were then fed back to the entire group. Any differences in the responses were discussed until a group agreement was obtained.
Estimates of effectiveness and key assumptions
The values of HMG were not estimated directly but were assumed to be similar to those observed with uFSH. The dropout rate for non-medical reasons was assumed to be 0.2 in the first cycle and 0.4 in the second cycle, regardless of the treatment chosen. The probability of becoming pregnant over the first three cycles of IVF treatments was assumed to be constant.
Measure of benefits used in the economic analysis
The summary benefit measure used in the economic analysis was the cumulative ongoing pregnancy rate after three cycles, which was estimated through the decision model.
Direct costs
Discounting was not relevant because the costs were considered over the first 12 weeks of pregnancy only. The unit costs were analysed separately from the quantities of resources used. The health services included in the economic analysis were IVF procedure, with or without embryo transfer, and drugs (uFSH, HMG, rFSH, nafarelin, progesterone, and human chorionic gonadotrophin). The cost/resource boundary of the study was that of the IVF provider clinic
